rps-28 Antibody

What is RPS28 and why is it important in cellular function?

RPS28 (also known as eS28 or 40S ribosomal protein S28) is a component of the small ribosomal subunit (40S) that plays an essential role in protein synthesis. It is critical for the biogenesis of 18S rRNA and functions as part of the small subunit (SSU) processome, which serves as the first precursor of the small eukaryotic ribosomal subunit . During assembly of the SSU processome in the nucleolus, RPS28 works with other ribosome biogenesis factors to facilitate RNA folding, modifications, rearrangements, and cleavage, as well as targeted degradation of pre-ribosomal RNA by the RNA exosome . Understanding RPS28 function provides fundamental insights into ribosome assembly and protein translation mechanisms that are essential for all cellular processes.

What species reactivity can be expected when using RPS28 antibodies?

Most commercially available RPS28 antibodies demonstrate cross-reactivity with multiple species. According to product information, rabbit polyclonal RPS28 antibodies typically react with human, mouse, and rat samples . This multi-species reactivity stems from the high conservation of ribosomal proteins across mammalian species. When planning experiments, researchers should verify the specific reactivity of their antibody with the intended experimental model. For applications involving other species, preliminary validation experiments should be conducted to confirm cross-reactivity before proceeding with full-scale studies.

What are the recommended applications for RPS28 antibodies?

RPS28 antibodies are validated for multiple experimental applications, including Western Blot (WB), Immunohistochemistry on paraffin-embedded tissues (IHC-P), Immunoprecipitation (IP), and Immunofluorescence (IF) . For optimal results in immunohistochemistry applications, researchers have reported successful staining using anti-RPS28 antibodies at a dilution of 1:100, followed by visualization with horseradish peroxidase-conjugated IgG and diaminobenzidine (DAB) . When performing western blot analysis, NETN lysis buffer has been effectively used for sample preparation . For each application, optimization of antibody concentration, incubation conditions, and detection methods may be necessary depending on the specific experimental setup and tissue/cell type being investigated.

How should RPS28 antibody be validated for osteosarcoma research?

For osteosarcoma research applications, comprehensive validation of RPS28 antibodies is essential given the protein's identified role as a potential therapeutic target in this cancer type . Validation should include:

• Positive controls: Use osteosarcoma cell lines with confirmed RPS28 expression (e.g., those used in published studies).

• Knockdown controls: Compare staining patterns between wild-type cells and those with RPS28 knockdown using siRNA or shRNA approaches.

• Clinical sample validation: Test antibody performance on osteosarcoma tissue microarrays with known clinical parameters.

• Cross-reactivity assessment: Ensure specificity by confirming lack of staining in RPS28-depleted samples.

Published research has successfully used RPS28 siRNA sequences including 5′-CCATCATCCGCAATGTAAA-3′, 5′-GCTCACCCTTTTGGAGTCA-3′, and 5′-TGCGCGTGGAATTCATGGA-3′ for knockdown experiments . After antibody validation, expression analysis can be performed using the NDP Nano Zoomer S210 scanning system and analyzed with NDP view 2.0 software or equivalent imaging platforms .

What are the optimal protocols for detecting RPS28 protein expression changes following gene silencing?

When investigating RPS28 expression changes following gene silencing, a systematic approach is recommended:

• Gene silencing options:

  • Transient knockdown: Use siRNA transfection with Lipofectamine 3000 following manufacturer's protocol. Specific siRNA sequences targeting RPS28 that have proven effective include: si-RPS28-1 (5′-CCATCATCCGCAATGTAAA-3′), si-RPS28-2 (5′-GCTCACCCTTTTGGAGTCA-3′), and si-RPS28-3 (5′-TGCGCGTGGAATTCATGGA-3′) .

  • Stable knockdown: Construct shRNA vectors based on effective siRNA sequences, followed by hygromycin B selection (800 μg/mL) .

• Expression analysis protocol:

  • Harvest cells 48-72 hours post-transfection.

  • Prepare protein lysates using NETN lysis buffer .

  • Perform western blot using validated anti-RPS28 antibody dilutions.

  • Include appropriate loading controls (β-actin or GAPDH).

  • Quantify relative expression using densitometry software.

• Validation of knockdown effects:

  • Perform parallel RNA analysis using RT-qPCR to distinguish between translational and transcriptional effects.

  • Assess functional consequences using proliferation, migration, or invasion assays depending on the research focus.

This comprehensive approach enables accurate assessment of RPS28 protein expression changes while distinguishing between transcriptional and translational regulation mechanisms.

How can researchers effectively analyze RPS28 localization in subcellular compartments?

To effectively analyze RPS28 subcellular localization, researchers should employ a multi-method approach:

• Immunofluorescence microscopy:

  • Fix cells with 4% paraformaldehyde (10-15 minutes, room temperature).

  • Permeabilize with 0.1% Triton X-100 (5-10 minutes).

  • Block with 5% BSA in PBS (1 hour).

  • Incubate with validated RPS28 antibody at optimized dilution (overnight, 4°C).

  • Apply fluorescently-labeled secondary antibody (1-2 hours, room temperature).

  • Counterstain nuclei with DAPI.

  • Image using confocal microscopy.

• Subcellular fractionation and western blot:

  • Separate nuclear, cytoplasmic, and nucleolar fractions using differential centrifugation.

  • Perform western blot analysis on each fraction.

  • Include compartment-specific markers (e.g., nucleolin for nucleoli, histone H3 for nucleus).

• Co-localization studies:

  • Perform double immunostaining with RPS28 antibody and markers for nucleolus (fibrillarin), processing bodies (DCP1a), or stress granules (G3BP1).

  • Calculate co-localization coefficients using appropriate software.

This approach provides comprehensive insights into RPS28 dynamics between different cellular compartments, particularly important when studying its roles in ribosome biogenesis in the nucleolus versus mature ribosome function in the cytoplasm.

How does RPS28 expression relate to osteosarcoma prognosis and what techniques are optimal for clinical assessment?

Recent research has identified RPS28 as a potential prognostic marker in osteosarcoma. High expression of RPS28 has been correlated with poor prognosis based on Kaplan-Meier survival analyses of TARGET-OSA and GSE21257-OSA datasets . For clinical assessment:

• Tissue preparation and immunohistochemistry:

  • Fix osteosarcoma tissue in 4% paraformaldehyde.

  • Dehydrate and embed in paraffin.

  • Section at 4 μm thickness.

  • Stain with anti-RPS28 antibody (recommended dilution 1:100).

  • Visualize using horseradish peroxidase-conjugated IgG and diaminobenzidine (DAB) .

• Analysis methodology:

  • Scan stained samples using digital pathology systems (e.g., NDP Nano Zoomer S210).

  • Analyze with appropriate software (e.g., NDP view 2.0).

  • Apply semiquantitative scoring based on staining intensity and positive rate .

• Correlation with clinical parameters:

  • Integrate RPS28 expression data with patient demographic information and clinicopathological characteristics.

  • Perform Kaplan-Meier survival analysis and Cox regression analysis.

  • Establish cut-off values for high versus low expression based on median or ROC curve analysis.

This comprehensive approach enables objective assessment of RPS28 as a prognostic biomarker in osteosarcoma patients and facilitates comparison across different study cohorts.

What are the methodological considerations when investigating the role of RPS28 in Diamond-Blackfan anemia?

Diamond-Blackfan anemia (DBA) has been linked to mutations in RPS28 , necessitating specific methodological approaches:

• Mutation screening protocols:

  • Design primers flanking all RPS28 exons and exon-intron boundaries.

  • Perform PCR amplification and direct sequencing.

  • Compare obtained sequences with reference sequences to identify variants.

  • Use computational tools to predict functional impacts of identified mutations.

• Functional validation approaches:

  • Establish cell models expressing wild-type or mutant RPS28.

  • Assess ribosome biogenesis using sucrose gradient fractionation to analyze polysome profiles.

  • Quantify pre-rRNA processing using northern blot or qRT-PCR targeting specific intermediates.

  • Evaluate cellular stress responses, particularly p53 activation, which is implicated in DBA pathophysiology.

• Hematopoietic differentiation assays:

  • Generate induced pluripotent stem cells (iPSCs) from patient samples or introduce RPS28 mutations in control iPSCs.

  • Differentiate iPSCs into hematopoietic progenitors and erythroid cells.

  • Assess cell proliferation, apoptosis, and erythroid maturation.

  • Analyze gene expression profiles to identify downstream pathways affected by RPS28 mutations.

These methodologies enable comprehensive investigation of the molecular mechanisms by which RPS28 mutations contribute to Diamond-Blackfan anemia pathogenesis.

How should researchers investigate the role of RPS28 in cancer cell survival and proliferation?

To investigate RPS28's role in cancer cell survival and proliferation, researchers should implement a comprehensive experimental strategy:

• Expression modulation:

  • Knockdown: Use validated siRNA sequences for transient knockdown or construct shRNA vectors for stable knockdown .

  • Overexpression: Create expression vectors containing wild-type or mutant RPS28 sequences.

• Functional assays:

  • Proliferation: MTT/XTT assays or real-time cell analysis systems.

  • Apoptosis: Annexin V/PI staining followed by flow cytometry.

  • Cell cycle analysis: PI staining and flow cytometry.

  • Invasion and migration: Transwell or wound healing assays.

• Mechanistic studies:

  • Perform RNA sequencing after RPS28 knockdown to identify differentially expressed genes (DEGs) .

  • Analyze enriched pathways using KEGG pathway analysis (p < 0.01 and FDR < 0.05) .

  • Focus on specific pathways implicated in cancer, such as the MAPK signaling pathway which has been shown to be affected by RPS28 silencing in osteosarcoma .

• In vivo validation:

  • Establish xenograft models using cells with modulated RPS28 expression.

  • Monitor tumor growth, metastasis, and animal survival.

  • Perform immunohistochemistry on tumor sections to evaluate pathway activation.

This systematic approach enables comprehensive characterization of RPS28's role in cancer biology and identification of potential therapeutic strategies targeting this protein.

What strategies can resolve contradictory results in RPS28 functional studies between mouse and human models?

Researchers may encounter contradictory results when studying RPS28 function across species due to differences in mRNA structure and regulatory mechanisms. To address these differences:

• Target site comparison:

  • Analyze the secondary structure of RPS28 mRNA in different species using methods like icSHAPE (in vivo click selective 2′-hydroxyl acylation and profiling experiment) .

  • Compare conservation of regulatory elements, particularly target sites for post-transcriptional regulators like LeuCAG3′tsRNA.

  • For mouse Rps28, recognize that while target site A in the coding sequence is highly conserved between mouse and human, target site B in the 3′ UTR differs significantly .

• Species-specific experimental design:

  • Create species-specific mutants that alter mRNA nucleotides without changing amino acid sequence.

  • For mouse studies, focus on target site A mutations, as target site B appears less functional in mouse models .

  • When developing expression constructs, maintain comparable codon usage to avoid introducing bias.

• Translation efficiency assessment:

  • Perform sucrose gradient fractionation to analyze polysome profiles.

  • Extract RNA from gradient fractions for northern blot analysis.

  • Compare polysome distribution patterns of RPS28 mRNA between species.

  • Include appropriate control mRNAs (e.g., NOP10, GAPDH) that should not be differentially affected .

These approaches help reconcile species-specific differences in RPS28 regulation and function, enabling more accurate translation of findings across experimental models.

How can researchers optimize RPS28 antibody-based detection in tissues with varying expression levels?

Optimizing RPS28 antibody-based detection across tissues with varying expression levels requires a systematic approach:

• Titration and signal amplification:

  • Perform antibody titration experiments (1:50 to 1:500 dilutions) on control tissues with known expression levels.

  • For low-expressing tissues, employ signal amplification methods such as:

    • Tyramide signal amplification (TSA) for immunohistochemistry

    • Enhanced chemiluminescence (ECL) plus or super signal systems for western blots

    • Quantum dot-conjugated secondary antibodies for immunofluorescence

• Antigen retrieval optimization:

  • Compare different antigen retrieval methods:

    • Heat-induced epitope retrieval (HIER) with citrate buffer (pH 6.0)

    • HIER with EDTA buffer (pH 9.0)

    • Enzymatic retrieval with proteinase K

  • Determine optimal retrieval duration for each tissue type

• Detection system selection:

  • For immunohistochemistry: Compare DAB, AEC, and alkaline phosphatase-based detection

  • For fluorescence: Test various fluorophores and mounting media to minimize autofluorescence

• Background reduction strategies:

  • Increase blocking duration (3-5% BSA or 10% normal serum, 1-2 hours)

  • Add 0.1-0.3% Triton X-100 to antibody diluent

  • Include 0.1-0.3% Tween-20 in wash buffers

  • Preabsorb antibody with tissue powder from non-expressing tissues

These optimizations enable reliable detection across tissues with variable RPS28 expression, reducing both false-negative results in low-expressing tissues and signal saturation in high-expressing samples.

What are the critical considerations when investigating the translational regulation of RPS28 by small RNAs?

Investigating translational regulation of RPS28 by small RNAs, particularly LeuCAG3′tsRNA, requires specific methodological considerations:

• Small RNA inhibition strategies:

  • Design antisense oligonucleotides (ASOs) targeting specific small RNAs like LeuCAG3′tsRNA.

  • Include appropriate control ASOs with similar chemical modifications but non-targeting sequences.

  • Perform dose-response experiments to determine optimal inhibition conditions.

• Translation efficiency analysis:

  • Perform sucrose gradient fractionation to separate monosomes and polysomes.

  • Extract RNA from each fraction for northern blot or qRT-PCR analysis.

  • Quantify relative distribution of RPS28 mRNA across gradient fractions.

  • Calculate the ratio of mRNA in lighter versus heavier polysomal fractions to assess translational efficiency .

  • Include control mRNAs (e.g., NOP10, GAPDH) that should not be affected by the small RNA of interest .

• Target site validation:

  • Create expression constructs with wild-type or mutated target sites.

  • Ensure mutations preserve amino acid sequence when modifying coding regions.

  • Co-transfect these constructs with control or inhibitory ASOs.

  • Analyze protein expression by western blot and RNA levels by qRT-PCR.

  • For mouse RPS28, note that target site A (in the coding sequence) appears more functional than target site B (in the 3′UTR) .

• Downstream effect assessment:

  • Monitor changes in pre-rRNA processing by northern blot analysis.

  • Quantify 18S and 28S rRNA levels (with expected specific effects on 18S but not 28S) .

  • Analyze accumulation of specific pre-rRNA species (e.g., 34S pre-rRNA in mouse models, equivalent to 30S pre-rRNA in human models) .

This comprehensive approach enables detailed characterization of translational regulatory mechanisms affecting RPS28 expression and subsequent effects on ribosome biogenesis.

What RNA sequencing protocols are recommended for studying differential gene expression after RPS28 knockdown?

For comprehensive analysis of transcriptional changes following RPS28 knockdown, the following RNA sequencing protocol is recommended:

• Sample preparation:

  • Perform RPS28 knockdown using validated siRNA sequences (si-RPS28-1, si-RPS28-2, or si-RPS28-3) with appropriate controls .

  • Extract total RNA using TRIzol reagent 48-72 hours post-transfection .

  • Verify RNA quality using bioanalyzer (RIN > 8.0).

  • Prepare libraries using poly(A) selection to enrich for mRNAs.

• Sequencing parameters:

  • Platform: Illumina NovaSeq or equivalent high-throughput system.

  • Read configuration: 150 bp paired-end reads.

  • Sequencing depth: Minimum 30 million reads per sample.

  • Include at least 3 biological replicates per condition.

• Data analysis workflow:

  • Quality control: FastQC followed by adapter trimming and quality filtering.

  • Alignment: STAR aligner to appropriate reference genome.

  • Quantification: HTSeq-count or featureCounts for gene-level counts.

  • Differential expression: R package limma with significance thresholds of fold-change > 1.5 or < 0.67 (|log2FC| ≥ 0.585) and p-value < 0.05 .

• Pathway analysis:

  • Perform KEGG pathway enrichment analysis with stringent cutoffs (p < 0.01 and FDR < 0.05) .

  • Focus on pathways previously implicated in RPS28 function, such as MAPK signaling.

  • Validate key findings using qRT-PCR and western blot analyses.

This comprehensive approach enables identification of transcriptional networks affected by RPS28 depletion and provides insights into its role in cellular processes beyond direct ribosomal functions.